Replies to post #229 on TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

imho,

... a masterpiece.

Thank you for posting and congratulations to all the authors, investigators, and TScan mgmt.

All the best to the TScan team at the Tandem meetings.

[FACT-MASTER]

Question: Given the results published thus far on the TSC-100 / TSC-101 trial, and knowing this is second line treatment post HCT, as per the approved trial NCT05473910;

When would TSC-100 / TSC-101 go into a first line treatment scenario trial?

Is that even possible in the current trial or would a new trial (IND) need to be initiated / approved.

When analysing the donor chimerism data on the February Presentation - slide 14 and additional abstract results...

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

...it demonstrates imo, that TSC-100 / TSC-101 should be first line treatment.

[FACT-MASTER]

Upcoming Poster Presentations include 2 Non-Clinical Presentations:

Question: Does this mean that they these therapies do not need FDA approval ?

Title: Nonclinical Development of T-Plex Component TSC-204-A0101: A Natural TCR-T Cell Therapy for the Treatment of MAGE-A1- and HLA-A*01:01-Positive Cancers
Presenter: Shazad Khokhar, Ph.D.
Abstract Number: 834
Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: Wednesday, May 8; 12:00 p.m. Eastern Time
Location: Exhibit Hall

Title: Non-Clinical Development of T-Plex Component TSC-201-B0702: A TCR-T Cell Therapy Directed to a Novel HLA-B*07:02 Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors
Presenter: Hannah Bader, Ph.D.
Abstract Number: 835
Session Title: Wednesday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: Wednesday, May 8; 12:00 p.m. Eastern Time
Location: Exhibit Hall